Table 1.
Baseline characteristics, prophylaxis, responses, and outcomes of study patients.
| Variables | Total = 122 (Number, %) |
|---|---|
| Sex (male) | 59 (48.4) |
| Age, years (median, IQR) | 61 (47–70) |
| AML type at diagnosis | |
| De novo/MRC | 97 (79.5) |
| Secondary | 21 (17.2) |
| Therapy-related | 4 (3.3) |
| AML status at initiation of VEN-based therapy | |
| Newly diagnosed | 39 (32.0) |
| Refractory/relapsed | 83 (68.0) |
| Prior treatment before VEN-based therapy | |
| Naïve | 39 (32.0) |
| Intensive chemotherapy | 38 (31.1) |
| Hypomethylating agents | 9 (7.4) |
| HSCT | 36 (29.5) |
| AML risk group | |
| Favorable | 25 (20.5) |
| Moderate | 46 (37.7) |
| Poor | 51 (41.8) |
| Combination agents | |
| Decitabine | 113 (92.6) |
| Azacitidine | 6 (4.9) |
| Low-dose cytarabine | 3 (2.5) |
| Overall response | |
| CR + CRi | 56 (45.9) |
| MLFS | 11 (9.0) |
| Non response | 51 (41.8) |
| Not available | 4 (3.3) |
| Completion of VEN-based therapy | 104 (85.3) |
| HSCT | 46 (44.2) |
| Non response | 24 (23.1) |
| Death | 23 (22.1) |
| Other reasons | 11 (10.6) |
| Total cycle of VEN-based therapy (median, range) | 2 (1–10) |
| Cycle of response achievement (median, range) | 1 (1–4) |
| Antifungal agents | 122 (100) |
| Empirical or targeted | 14 (11.5) |
| Antifungal prophylaxis | 108 (88.5) |
| Fluconazole | 106 (98.1) |
| Posaconazole | 2 (1.9) |
| Overall mortality | 53 (43.4) |
AML: acute myeloid leukemia; CR: complete recovery; CRi: complete recovery with incomplete hematologic recovery; HSCT: hematopoietic stem cell transplantation; IQR: interquartile range; MLFS: morphologic leukemia free state; MRC: myelodysplasia-related changes; VEN: venetoclax.